Clinical Trial

HRD Tests for Ovarian cancER

Study acronym: HERO
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study concerns patients with Invasive epithelial ovarian cancer, primary Fallopian tube carcinoma, ovarian-type peritoneal carcinoma, and with an indication of a first-line platinum-based chemotherapy. To determine HRD status, 2 separate tests will be performed in the study: 1. Giscar assay : developed by the sponsor 2. myChoice assay If one or two tests identifies a HRD status : a PARP inhibitor treatment may be initiated according to current recommendations
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-11-22; most recent amendment 2025-09-16.
Status change: Not Yet Recruiting → Recruiting 2024-02-19
Trial Details
NCT Number NCT06152731
Lead Sponsor Centre Francois Baclesse
Conditions Ovarian Cancer
Enrollment 88 participants
Start Date 2024-02-15
Primary Completion 2031-06 (estimated)
Study Completion 2031-06 (estimated)
Updated on ClinicalTrials.gov 2025-09-17